Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
87 hedge funds and large institutions have $202M invested in Concert Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 23 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
10% more call options, than puts
Call options by funds: $3.21M | Put options by funds: $2.92M
5% less funds holding
Funds holding: 92 → 87 (-5)
6% less capital invested
Capital invested by funds: $215M → $202M (-$12.9M)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$7.01M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.95M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$2.61M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$2.38M |
| 5 |
ISL
Ingalls & Snyder LLC
New York
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$20.4M |
| 2 |
First Manhattan
New York
|
-$5.47M |
| 3 |
Millennium Management
New York
|
-$3.25M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.09M |
| 5 |
DMK
David M. Knott
|
-$1.01M |
CNCE Hedge Fund Activity: Q2 2019 in Review
87 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2019, worth a combined $202M — down 6% from $215M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of CNCE and 20 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 35 added.
The largest buyer was Bank of America, adding an estimated $7.01M. The largest seller was RTW Investments, exiting entirely with an estimated $20.4M sold.
- 87 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2019, down from 92 in Q1 2019.
- Funds reported $202M of Concert Pharmaceuticals, Inc. stock for Q2 2019, down 6% quarter-over-quarter.
- 20 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2019 and 23 closed out, a net change of -3 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2019 was Bank of America, an estimated $7.01M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2019 was RTW Investments, an estimated $20.4M sold.
Based on aggregated 13F filings for Q2 2019.